Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data ...
Pharmaceutical Executive spoke with John Stanford, executive director at Incubate, about the current status of MFN and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results